Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

938 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study.
Stilgenbauer S, Leblond V, Foà R, Böttcher S, Ilhan O, Knauf W, Mikuskova E, Renner C, Tausch E, Woszczyk D, Gresko E, Lundberg L, Moore T, Morris T, Robson S, Bosch F. Stilgenbauer S, et al. Among authors: foa r. Leukemia. 2018 Aug;32(8):1778-1786. doi: 10.1038/s41375-018-0146-5. Epub 2018 Apr 27. Leukemia. 2018. PMID: 29749403 Free PMC article. Clinical Trial.
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Breccia M, Palandri F, Iori AP, Colaci E, Latagliata R, Castagnetti F, Torelli GF, Usai S, Valle V, Martinelli G, Rosti G, Foà R, Baccarani M, Alimena G. Breccia M, et al. Among authors: foa r. Leuk Res. 2010 Feb;34(2):143-7. doi: 10.1016/j.leukres.2009.04.036. Epub 2009 May 29. Leuk Res. 2010. PMID: 19481800
Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma.
Cavalieri E, Matturro A, Annechini G, De Angelis F, Frattarelli N, Gentilini F, Grapulin L, Sacco M, Torelli F, Vignetti M, Mandelli F, Foà R, Pulsoni A. Cavalieri E, et al. Among authors: foa r. Leuk Lymphoma. 2009 Nov;50(11):1803-8. doi: 10.3109/10428190903254383. Leuk Lymphoma. 2009. PMID: 19860621 Clinical Trial.
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.
Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, Benoit Y, Biondi A, Cavé H, Dombret H, Fielding AK, Foà R, Gökbuget N, Goldstone AH, Goulden N, Henze G, Hoelzer D, Janka-Schaub GE, Macintyre EA, Pieters R, Rambaldi A, Ribera JM, Schmiegelow K, Spinelli O, Stary J, von Stackelberg A, Kneba M, Schrappe M, van Dongen JJ; European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); International Berlin-Frankfurt-Münster Study Group (I-BFM-SG). Brüggemann M, et al. Among authors: foa r. Leukemia. 2010 Mar;24(3):521-35. doi: 10.1038/leu.2009.268. Epub 2009 Dec 24. Leukemia. 2010. PMID: 20033054 Review.
Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors.
Tavolaro S, Chiaretti S, Messina M, Peragine N, Del Giudice I, Marinelli M, Santangelo S, Mauro FR, Guarini A, Foà R. Tavolaro S, et al. Among authors: foa r. Leuk Res. 2010 Jun;34(6):733-41. doi: 10.1016/j.leukres.2009.11.005. Epub 2009 Dec 24. Leuk Res. 2010. PMID: 20036005
938 results